Champions Oncology, Inc.

191 articles about Champions Oncology, Inc.

• Champions Oncology Announces the Expansion of Lumin Bioinformatics: Now Featuring a Highly Valuable Set of Proteomic Data and Analytics

  1/5/2021

  Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-driven research strategies, announced today the expansion of its SaaS program, Lumin Bioinformatics .

• Champions Oncology Reports Record Quarterly Revenue of $10.1 Million

  12/14/2020

  Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced its financial results for the second fiscal quarter ended October 31, 2020. Second Quarter and Recent Highlights:

• Champions Oncology to Announce Second Quarter Financial Results on Monday, December 14, 2020

  12/7/2020

  Champions Oncology, Inc., a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced it will report its financial and operational results for the second quarter ended October 31, 2020, on Monday, December 14, 2020, after market close.

• Champions Oncology Announces the Launch of Lumin Bioinformatics, Its New Oncology Data-Driven SaaS Program

  11/16/2020

  Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced today the launch of its new proprietary SaaS program known as Lumin Bioinformatics .

• Champions Oncology Expands Its Immuno-Oncology Research Offering by Launching a Unique Autologous Tumor Infiltrating Lymphocyte Ex Vivo Platform

  11/11/2020

  Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced today the launch of a novel autologous immuno-oncology (IO) research platform.

• Champions Oncology to Announce First Quarter Financial Results on Monday, September 14, 2020

  9/8/2020

  Champions Oncology, Inc., engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, announced it will report its financial and operational results for the first quarter ended July 31, 2020, on Monday, September 14, 2020, after market close.

• Champions Oncology to Announce Fourth Quarter Financial Results on Monday, July 27, 2020

  7/22/2020

  Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the quarter and year ended April 30, 2020, on Monday,

• Champions Oncology to Announce Second Quarter Financial Results on Monday, December 17, 2018

  12/10/2018

  Champions Oncology, Inc. today announced it will report its financial and operational results for the second quarter ended October 31, 2018, on Monday, December 17, 2018.

• Patients Launch New Study to Shed Light on EGFR-Positive Lung Cancers

  11/15/2018

  Scientists, physicians and patients collaborate to improve treatment for rare cancer

• Champions Oncology to Participate in the 9th Annual Craig-Hallum Alpha Select Conference

  11/7/2018

  Champions Oncology, Inc. today announced that management, will participate in the 9th annual Craig-Hallum Alpha Select conference on Thursday, November 15, 2018, in New York.

• Champions Oncology Reports Record Quarterly Revenue of $6.2 Million

  9/13/2018

  Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019

• Champions Oncology Granted Full Accreditation by the AAALAC

  8/8/2018

  Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that its new facility in Rockville, MD has been granted Full Accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.

• Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018

  7/26/2018

  Expects Revenue Growth of at Least 20% for Fiscal Year 2019

• Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 26, 2018

  7/12/2018

  Champions Oncology, Inc. announced it will report its financial and operational results for the fourth quarter ended April 30, 2018, on Thursday, July 26, 2018, after market close.

• Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies

  6/18/2018

  Champions Oncology, Inc. announced that they have partnered with NSABP Foundation, Inc. and Puma Biotechnology, Inc. to develop patient derived xenograft (PDX) models in two multi-center co-clinical PDX trials.

• Champions Oncology to Present at the 3rd annual Disruptive Growth & Healthcare Conference on May 9th

  5/3/2018

  Champions Oncology, Inc. announced that management will be presenting at the 3rd annual Disruptive Growth & Healthcare Conference on Wednesday, May 9th at 8:40am.

• Champions Oncology Adds Amy Wesa, Ph.D, as Director of Immuno-Oncology Research

  5/1/2018

  Champions Oncology, Inc. announced that Amy Wesa, Ph.D, has joined the company as Director of Immuno-Oncology Research.

• Champions Oncology Reports Quarterly Revenue of $5.1 Million

  3/15/2018

  Champions Oncology, Inc. announced its financial results for the third fiscal quarter and nine months ended January 31, 2018.

• Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 15, 2018

  3/7/2018

  Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2018, on Thursday, March 15, 2018, after market close.

• Champions Oncology Reports Record Quarterly Revenue of $5.2M

  12/8/2017

  Champions Oncology today announced its financial results for the second fiscal quarter and six months ended October 31, 2017.